Celgene signs $1.5bn partnership with Immatics to fight cancer with engineered T-cell therapies
pharmafile | August 29, 2019 | News story | Research and Development | Cancer, Celgene, immatics, immunotherapy, pharma
Celgene and biopharma firm Immatics Biotechnologies have announced that they have entered a partnership valued at a potential $1.5 billion to pursue the development of T-cell receptor-engineered T-cell therapies (TCR-T) for a range of cancer types.
The pair will leverage Immatics’ XPRESIDENT technology and XCEPTOR TCR discovery and engineering platform to develop immunotherapies based on the method of engineering T-cells of patients to express a specific receptor.
As part of the deal, Immatics will receive an upfront payment of $75 million for three programmes, and is eligible to receive an additional $505 million for each programme that achieves prespecified developmental and commercial milestones. Celgene will have the option to assume worldwide commercial and manufacturing responsibility for any of these therapies, though Immatics maintains early stage co-development rights or co-funding rights for selected products developed as part of the collaboration.
“We are delighted to enter into this strategic collaboration with Celgene. This alliance leverages Immatics’ excellence in developing adoptive cell therapies (ACT) and complements our proprietary clinical pipeline of ACT products and our strong portfolio of Bispecific products”, explained Harpreet Singh, CEO of Immatics. “By combining Immatics’ world-leading discovery engines as well as our cellular manufacturing and clinical development platforms with Celgene’s broad expertise in cell therapy research, development and commercialisation, the companies join forces to enable the development of truly novel opportunities for patients with solid tumours who currently have no other treatment options.”
Matt Fellows
Related Content
Geneos Therapeutics shares data from phase 1/2 trial for cancer vaccine
Geneos Therapeutics has announced that it has published positive safety, immunogenicity and efficacy data from …
Curve Therapeutics’ CSO publishes research on HIF inhibition for cancer treatment
Curve Therapeutics has announced that its chief scientific officer, Professor Ali Tavassoli has published research …
Verastem Oncology gains Fast Track Designation for combination NSCLC treatment
Verastem Oncology has announced that the US Food and Drug Administration (FDA) has granted Fast …
